Zoetis Inc. (NYSE:ZTS) – Equities research analysts at Jefferies Group issued their Q3 2016 earnings per share (EPS) estimates for shares of Zoetis in a report released on Thursday. Jefferies Group analyst J. Holford expects that the firm will post earnings of $0.46 per share for the quarter. Jefferies Group currently has a “Buy” rating and a $60.00 target price on the stock. Jefferies Group also issued estimates for Zoetis’ FY2016 earnings at $1.90 EPS.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. Zoetis had a net margin of 13.15% and a return on equity of 77.58%. The business earned $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the firm posted $0.43 EPS. Zoetis’s revenue was up 2.8% compared to the same quarter last year.
Other analysts also recently issued research reports about the company. Argus boosted their price objective on Zoetis from $54.00 to $58.00 and gave the company a “below average” rating in a research report on Friday, September 9th. Credit Suisse Group AG restated an “outperform” rating and set a $60.00 target price on shares of Zoetis in a report on Tuesday, August 23rd. Barclays PLC upped their target price on Zoetis from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Thursday, August 4th. Stifel Nicolaus restated a “buy” rating and set a $58.00 target price on shares of Zoetis in a report on Wednesday. Finally, Citigroup Inc. upped their target price on Zoetis from $50.00 to $53.00 and gave the company a “neutral” rating in a report on Thursday, August 4th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $55.27.
Zoetis (NYSE:ZTS) opened at 50.18 on Friday. The stock has a market capitalization of $24.84 billion, a P/E ratio of 39.08 and a beta of 1.01. The firm’s 50-day moving average is $51.25 and its 200-day moving average is $49.01. Zoetis has a 12-month low of $38.26 and a 12-month high of $53.14.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Thursday, November 3rd will be paid a $0.095 dividend. The ex-dividend date is Tuesday, November 1st. This represents a $0.38 dividend on an annualized basis and a dividend yield of 0.76%. Zoetis’s dividend payout ratio is currently 29.69%.
In related news, insider Heidi C. Chen sold 32,097 shares of the stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $50.98, for a total transaction of $1,636,305.06. Following the sale, the insider now directly owns 46,060 shares of the company’s stock, valued at $2,348,138.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael B. Mccallister acquired 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 6th. The shares were acquired at an average cost of $51.34 per share, for a total transaction of $102,680.00. The disclosure for this purchase can be found here. 0.05% of the stock is owned by insiders.
Several large investors have recently added to or reduced their stakes in the stock. NEXT Financial Group Inc boosted its stake in Zoetis by 9.5% in the second quarter. NEXT Financial Group Inc now owns 2,136 shares of the company’s stock valued at $101,000 after buying an additional 186 shares during the period. Kelly Lawrence W & Associates Inc. CA boosted its stake in Zoetis by 113.4% in the second quarter. Kelly Lawrence W & Associates Inc. CA now owns 2,446 shares of the company’s stock valued at $116,000 after buying an additional 1,300 shares during the period. NN Investment Partners Holdings N.V. acquired a new stake in Zoetis during the first quarter valued at approximately $118,000. Northwestern Mutual Wealth Management Co. boosted its stake in Zoetis by 22.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,566 shares of the company’s stock valued at $121,000 after buying an additional 476 shares during the period. Finally, Glenmede Trust Co. NA boosted its stake in Zoetis by 4.4% in the second quarter. Glenmede Trust Co. NA now owns 2,950 shares of the company’s stock valued at $139,000 after buying an additional 124 shares during the period. 93.12% of the stock is currently owned by institutional investors.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.